Tandem Diabetes Care (TNDM) Net Income towards Common Stockholders Growth (3y) (2016 - 2026)
Powered by 
Analysis
Tandem Diabetes Care (TNDM) Net Income towards Common Stockholders Growth (3y) (2016 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 179.84 Bn | 174.23 Bn | 7.27 Bn | -12.28% |
| 2 | Intuitive Surgical | 128.02 Bn | 122.81 Bn | 1.96 Bn | 24.56% |
| 3 | Medtronic | 117.28 Bn | 108.46 Bn | 6.34 Bn | 22.97% |
| 4 | Stryker | 103.92 Bn | 100.44 Bn | 4.50 Bn | 20.02% |
| 5 | Boston Scientific | 63.51 Bn | 62.97 Bn | 3.85 Bn | 51.47% |
| 6 | Edwards Lifesciences | 49.96 Bn | 45.70 Bn | 1.35 Bn | -7.83% |
| 7 | Alcon | 32.86 Bn | 31.40 Bn | 1.68 Bn | - |
| 8 | Dexcom | 32.25 Bn | 30.30 Bn | 830.00 Mn | 29.05% |
| 9 | Steris | 20.74 Bn | 20.26 Bn | 684.20 Mn | 17.54% |
| 10 | Tandem Diabetes Care | 1.26 Bn | 808.29 Mn | 144.78 Mn | 15.99% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 15.99% |
| Mar 31, 2026 | 45.18% |
| Dec 31, 2025 | 67.52% |
| Sep 30, 2025 | 24.42% |
| Jun 30, 2025 | -51.38% |
| Mar 31, 2025 | -107.04% |
| Dec 31, 2024 | -58.40% |
| Sep 30, 2024 | -82.17% |
| Jun 30, 2024 | -113.35% |
| Mar 31, 2024 | -103.33% |
| Dec 31, 2023 | -55.54% |
| Sep 30, 2023 | -51.71% |
| Jun 30, 2023 | -9.70% |
| Mar 31, 2023 | -102.59% |
| Dec 31, 2022 | -99.81% |
| Sep 30, 2022 | -156.52% |
| Jun 30, 2022 | -115.38% |
| Mar 31, 2022 | 13.82% |
| Dec 31, 2021 | 42.91% |
| Sep 30, 2021 | 29.42% |